Novo Nordisk has decided to permanently discontinue the manufacturing and distributing of all formulations of Levemir® (insulin detemir) and GlucaGen® HypoKit® in the U.S. market. Contributed factors to the Levemir®discontinuation decision includes global manufacturing constraints, significant formulary losses impacting patient access effective in January 2024, and the availability of alternative basal insulin options in the market. Novo Nordisk expects Levemir® FlexPen® supply disruptions to begin in mid-January 2024 followed by the complete discontinuation of Levemir® FlexPen® on April 1, 2024. Levemir® 10 mL vial is expected to be available until December 31, 2024, after which the full Levemir® brand will be discontinued. GlucaGen® HypoKit® will be discontinued in the U.S. on July 1, 2024, due to a global shortfall of pre-filled syringes from an external vendor. ProAct encourages patients to begin discussing an alternative treatment with their healthcare provider before products are no longer available.
